Traws Pharma (TRAW) awards 118,367 stock options to Chief Science Officer

Rhea-AI Filing Summary

Traws Pharma, Inc. reported that Chief Science Officer Virology Charles David Pauza received a grant of 118,367 stock options to buy common stock at an exercise price of $1.6000 per share. These options were awarded by the compensation committee under the company’s 2021 Incentive Compensation Plan and will vest 100% on the first anniversary of the March 8, 2026 grant date. Following this award, Pauza holds 118,367 options directly, and the options are scheduled to expire on March 8, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pauza Charles David

Role Chief Science Officer Virology

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	118,367	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 118,367 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pauza Charles David

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Science Officer Virology

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.6	03/08/2026		A		118,367		03/08/2027(1)	03/08/2036	Common Stock	118,367	$0	118,367	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Charles D. Pauza	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Traws Pharma (TRAW) report for Charles David Pauza?

Traws Pharma reported that Chief Science Officer Virology Charles David Pauza received a grant of 118,367 stock options. The options give him the right to buy common shares at $1.60 under the company’s 2021 Incentive Compensation Plan.

What are the key terms of the 118,367 stock options granted at Traws Pharma (TRAW)?

The 118,367 stock options allow purchase of Traws Pharma common stock at $1.60 per share. They were granted as compensation, vest 100% on the first anniversary of the grant date, and are scheduled to expire on March 8, 2036.

When do Charles David Pauza’s Traws Pharma (TRAW) stock options vest and expire?

All 118,367 stock options granted to Charles David Pauza vest 100% on the first anniversary of the March 8, 2026 grant date. According to the terms, these options are scheduled to remain exercisable until their expiration on March 8, 2036.

Is the Traws Pharma (TRAW) Form 4 transaction an open-market buy or a compensation grant?

The Form 4 shows a compensation-related grant, not an open-market purchase. Code A indicates a grant or award, and the footnote explains the 118,367 options were awarded by the compensation committee under the 2021 Incentive Compensation Plan.

How many Traws Pharma (TRAW) derivative securities does Charles David Pauza hold after this grant?

After the reported transaction, Charles David Pauza holds 118,367 stock options directly. The filing’s totals show this full amount following the grant, reflecting his position in these options as of the transaction date disclosed.